Current constitutional documents
Most recent admission document
Details of Any Other Exchanges or Trading Platforms
The company is not quoted on any other exchanges or trading platforms
Details of any Restrictions on the Transfer of Securities
There are no restrictions on the transfer of Abingdon Health securities
Whether the Company is subject to the UK City Code on Takeovers and Mergers
The company is subject to the UK City Code on Takeovers and Mergers
Country of Incorporation and Main Country of Operation
Abingdon Health was incorporated in England and Wales on 16 January 2008 (Registration No. 06475379) and is headquartered in York, UK, with an additional site in Doncaster.
Number of Securities in Issue
Issued share capital consists of 121,716,822 ordinary shares of 0.025p each.
AIM securities not in public hands
In so far as the Company is aware, the percentage of AIM securities not in public hands is: 32.03%.
Significant Shareholders (3% or over)
| Shareholder | Ordinary Shares | Issued Share Capital (%) |
|---|---|---|
| Enterprise Ventures (General Partner NPIF YHTV Equity) Ltd | 18,071,164 | 14.85% |
| Chris Hand | 13,028,467 | 10.70% |
| Hargreaves Lansdown Asset Mgt | 10,661,581 | 8.67% |
| Chris Yates | 7,888,844 | 6.48% |
| Catenalucis LLC | 7,588,488 | 6.23% |
| Interactive Investor | 6,698,617 | 5.50% |
| Thornapple LLP | 6,113,124 | 5.02% |
| Jarvis Investment Management | 4,172,356 | 3.43% |
| Touchstone Innovations Businesses LLP | 4,164,756 | 3.42% |
This information was last updated on 6th July 2023.
Description of business
Board and Governance
Documents and Reports
Regulatory Announcements
Advisors
Nominated Advisor and Broker:
Singer Capital Markets
One Bartholomew Lane
London EC2N 2AX
Solicitors to the Company:
Squire Patton Boggs (UK) LLP
6 Wellington Place
Leeds LS1 4AP
Reporting Accountant and Auditor:
BDO LLP
Central Square
29 Wellington Street
Leeds LS1 4DL
Registrar:
Link Group
The Registry
34 Beckenham Road
Beckenham
Kent BR3 4TU
Public Relations:
Walbrook PR Ltd
75 King William Street,
London
EC4N 7BE
Tel: 020 7933 8787
For all investor relations enquiries, please contact Walbrook PR at: [email protected].
